{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:15:29Z","timestamp":1792718129512,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The optimal duration of anticoagulant therapy in patients with cancer-associated venous thromboembolism (VTE) is unknown. Without well-designed studies evaluating the efficacy, safety, and cost-effectiveness of continuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recommendations are lacking. Consensus guidelines generally suggest continuing anticoagulation treatment in patients with active cancer or receiving cancer treatment, with periodic reassessment of the risks and benefits. Unfortunately, with very little published data on the epidemiology of cancer-associated VTE beyond the initial 6 months, it is not possible for clinicians and patients to weigh risks and benefits in a quantitatively informed manner. Further research is needed to provide reliable and contemporary estimates on the risk of recurrent VTE off anticoagulant therapy, risk of bleeding on anticoagulant therapy, case fatality or all-cause mortality, and other important consequences of living with cancer-associated VTE. This chapter provides an overview of the published literature on real-world data on anticoagulant therapy use, the risks and risk factors of recurrent VTE and bleeding, and patient preference and values regarding long-term anticoagulation treatment. It will conclude with a pragmatic, experience-informed approach for tailoring anticoagulant therapy in patients with cancer-associated VTE.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.128","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["When can we stop anticoagulation in patients with cancer-associated thrombosis?"],"prefix":"10.1182","volume":"2017","author":[{"given":"Agnes Y. Y.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Hematology, University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703515525400_B1","author":"Masseria"},{"issue":"4","key":"2019111703515525400_B2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.thromres.2014.07.027","article-title":"Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice","volume":"134","author":"Kaatz","year":"2014","journal-title":"Thromb Res"},{"issue":"11","key":"2019111703515525400_B3","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/jth.13483","article-title":"Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis","volume":"14","author":"Mah\u00e9","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111703515525400_B4","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111703515525400_B5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111703515525400_B6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019111703515525400_B7","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703515525400_B8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"1","key":"2019111703515525400_B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"issue":"25","key":"2019111703515525400_B10","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111703515525400_B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"issue":"6","key":"2019111703515525400_B12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"issue":"7","key":"2019111703515525400_B13","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2019111703515525400_B14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"2019111703515525400_B15","author":"Kamphuisen"},{"issue":"2","key":"2019111703515525400_B16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.thromres.2015.06.030","article-title":"Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study","volume":"136","author":"Heit","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"2019111703515525400_B17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111703515525400_B18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cct.2011.07.005","article-title":"Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism","volume":"32","author":"Parpia","year":"2011","journal-title":"Contemp Clin Trials"},{"issue":"2 Suppl","key":"2019111703515525400_B19","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"6","key":"2019111703515525400_B20","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2019111703515525400_B21","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"Mandal\u00e0","year":"2010","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"2019111703515525400_B22","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(16)30106-2","article-title":"Predictors of recurrent venous thromboembolism and bleeding on anticoagulation","volume":"140","author":"Menapace","year":"2016","journal-title":"Thromb Res"},{"issue":"2","key":"2019111703515525400_B23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MBC.0b013e328341f030","article-title":"Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies","volume":"22","author":"Louzada","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2019111703515525400_B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-994915","article-title":"The thrombophilic state induced by therapeutic agents in the cancer patient","volume":"25","author":"Lee","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"25","key":"2019111703515525400_B25","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703515525400_B26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2016.67.4564","article-title":"Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH Trial","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703515525400_B27","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","article-title":"Biomarkers for prediction of venous thromboembolism in cancer","volume":"122","author":"Pabinger","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111703515525400_B28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"2019111703515525400_B29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00007611-198007000-00005","article-title":"Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?","volume":"73","author":"Shen","year":"1980","journal-title":"South Med J"},{"issue":"3","key":"2019111703515525400_B30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2019111703515525400_B31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019111703515525400_B32","doi-asserted-by":"crossref","first-page":"832.e13","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort","volume":"126","author":"Tagalakis","year":"2013","journal-title":"Am J Med"},{"issue":"1","key":"2019111703515525400_B33","doi-asserted-by":"crossref","first-page":"1600282","DOI":"10.1183\/13993003.00282-2016","article-title":"Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study","volume":"49","author":"Font","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"2019111703515525400_B34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111703515525400_B35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jth.13563","article-title":"Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice","volume":"15","author":"van der Wall","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2019111703515525400_B36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients\u2019 Experiences of LIving with CANcer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2019111703515525400_B37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.06.005","article-title":"Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study","volume":"144","author":"Cajfinger","year":"2016","journal-title":"Thromb Res"},{"issue":"3","key":"2019111703515525400_B38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0269216305pm1008oa","article-title":"Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study","volume":"19","author":"Noble","year":"2005","journal-title":"Palliat Med"},{"issue":"11","key":"2019111703515525400_B39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2019111703515525400_B40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2011.07.017","article-title":"Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey","volume":"129","author":"Cimminiello","year":"2012","journal-title":"Thromb Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/128\/1250966\/hem00018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/128\/1250966\/hem00018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:52:22Z","timestamp":1573980742000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/128\/21154\/When-can-we-stop-anticoagulation-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.128","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}